Monocytic Gal-9 and PD-L1, expressed heterogeneously in different phases of CHI, exert diverse inhibitory effects on immune-responses and their therapeutic targeting could boost anti-HBV immunity. The gene discussed is LGALS9; the disease is congenital isolated hyperinsulinism.